Policy / Pricing 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) Drug ChannelsJoin Dr.Read full story pharminent May 12, 2026 (Last updated: May 12, 2026) Drug Channels Join Dr. Read full story Post navigation Previous: Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosisNext: BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial Related Stories Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026 Policy / Pricing Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain pharminent August 13, 2026 Policy / Pricing Trump signs order that nearly halves childhood immunisation coverage pharminent August 11, 2026
